epigallocatechin gallate has been researched along with cardiovascular agents in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Devika, PT; Prince, PS | 1 |
| Czernizer, E; Dardik, A; Dardik, H; Hoffmann, T; London, D; Naftalovich, R; Orozco-Sevilla, V; Yang, C | 1 |
| Nie, S; Wang, S; Zhang, J | 1 |
| Chakraborti, S; Chakraborti, T; Chowdhury, A; Sarkar, J | 1 |
| Eng, QY; Ramamurthy, S; Thanikachalam, PV | 1 |
| Gan, Y; Liu, J; Liu, L; Tian, J; Zhao, W | 1 |
1 review(s) available for epigallocatechin gallate and cardiovascular agents
| Article | Year |
|---|---|
Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases.
Topics: Animals; Anti-Inflammatory Agents; Camellia sinensis; Cardiovascular Agents; Cardiovascular Diseases; Catechin; Humans; Metabolic Diseases; Tea | 2018 |
5 other study(ies) available for epigallocatechin gallate and cardiovascular agents
| Article | Year |
|---|---|
Preventive effect of (-)epigallocatechin-gallate (EGCG) on lysosomal enzymes in heart and subcellular fractions in isoproterenol-induced myocardial infarcted Wistar rats.
Topics: Animals; Cardiovascular Agents; Catechin; Disease Models, Animal; Heart; Isoproterenol; Lysosomes; Male; Myocardial Infarction; Rats; Rats, Wistar; Subcellular Fractions; Time Factors | 2008 |
Epigallocatechin-3-gallate is a potent phytochemical inhibitor of intimal hyperplasia in the wire-injured carotid artery.
Topics: Animals; Cardiovascular Agents; Carotid Artery Injuries; Carotid Artery, Common; Carotid Intima-Media Thickness; Catechin; Cell Proliferation; Disease Models, Animal; Disulfides; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Hyperplasia; Injections, Intraperitoneal; Isothiocyanates; Male; Neointima; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Resveratrol; Stilbenes; Sulfinic Acids; Sulfoxides; Time Factors | 2013 |
Nanoencapsulation enhances epigallocatechin-3-gallate stability and its antiatherogenic bioactivities in macrophages.
Topics: Atherosclerosis; Camellia sinensis; Cardiovascular Agents; Catechin; Cell Line; Chemokine CCL2; Cholesterol; Drug Compounding; Drug Stability; Humans; Macrophages; Nanoparticles; Plant Extracts | 2013 |
Role of Spm-Cer-S1P signalling pathway in MMP-2 mediated U46619-induced proliferation of pulmonary artery smooth muscle cells: protective role of epigallocatechin-3-gallate.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Cardiovascular Agents; Cardiovascular Diseases; Catechin; Cattle; Cell Culture Techniques; Cell Proliferation; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Myocytes, Smooth Muscle; Pulmonary Artery; Vasoconstrictor Agents | 2015 |
Epigallocatechin-3 gallate prevents pressure overload-induced heart failure by up-regulating SERCA2a via histone acetylation modification in mice.
Topics: Acetylation; Animals; Aortic Diseases; Cardiovascular Agents; Catechin; Constriction, Pathologic; Disease Models, Animal; Heart Failure; Histone Deacetylase 1; Histones; Male; Mice, Inbred C57BL; Promoter Regions, Genetic; Protective Agents; Random Allocation; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Up-Regulation | 2018 |